ANKE BIO: Innovative drug HuA21 injection will announce clinical research data at the 2025 European Society for Medical Oncology (ESMO) annual meeting
I'm PortAI, I can summarize articles.
ANKE BIO announced that it will present the clinical research data of its innovative drug HuA21 at the 2025 European Society for Medical Oncology (ESMO) annual meeting. The study of the drug in combination with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric cancer has shown good anti-tumor activity and safety, supporting the Phase III clinical trial and enhancing the product's market competitiveness
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments